Articles tagged "Adverse effects"

2017 American Transplant Congress
Systemic Immunosuppression in the Setting of Ocular Surface Stem Cell Transplantation.
A. Govil,¹ A. Cheung,² E. Sarnicola,² E. Holland.²
¹University of Cincinnati, Cincinnati, OH; ²Cincinnati Eye Institute, Cincinnati, OH
Purpose: To evaluate the success, tolerability, and side effects of systemic immunosuppression (SI) in patients undergoing ocular surface stem cell transplantation (OSST) under the SI…
2017 American Transplant Congress
Improvement of Cyclosporine A Dosing Strategy to Enhance Medication Adherence.
M. Barten,¹ E. Harmel,¹ M. Goldmann,¹ F. Wagner,¹ H. Reichenspurner,¹ M. Rybczynski.²
¹Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany; ²General and Interventional Cardiology, University Heart Center Hamburg, Hamburg, Germany
Background: It is known that the number of daily pills is crucial for medical adherence of patients after heart transplantation (HTx). For cyclosporine A (CsA)…
2017 American Transplant Congress
This is Why We Can't Have Nice Things- Real World Experience with Everolimus in Livers.
C. Perez,¹ J. Fleming,¹ M. Sell,¹ B. O'Brien,¹ A. Rogers,¹ I. Lee,¹ C. Mardis,¹ A. Mardis,¹ N. Patel,¹ H. Meadows,¹ N. Pilch,² K. Chavin,² D. Dubay,² D. Taber.²
¹Pharmacy, Medical University of South Carolina, Chareleston, SC; ²Surgery, Medical University of South Carolina, Charleston, SC
Purpose: To determine if discontinuation rates of everolimus (RAD) in clinical practice is higher than the 30% demonstrated in trials.Methods: This was a retrospective cohort…
2017 American Transplant Congress
An Investigation of Biopsy-Proven De Novo Autoimmune Hepatitis After Hepatitis C Clearance with Direct Acting Antivirals in Liver Transplant Patients.
R. Sigireddi, J. Moffett, M. Kueht, R. Ackah, A. Rana, C. O'Mahony, J. Goss, S. Dhingra, S. Khaderi.
Department of Abdominal Transplantation, Baylor College of Medicine, Houston, TX
Direct acting antivirals (DAAs) for hepatitis C virus (HCV) have been widely prescribed to post-liver transplant patients for HCV clearance and are believed to be…
2016 American Transplant Congress
Evolving to Everolimus: A Safe and Effective Option for Pancreas Transplant.
S. Yeager, A. Carlson, C. Truax, N. Kenyon, F. Ahmed, J. Corbett, F. Shihab, L. Smith.
University of Utah Health Care, Salt Lake City, UT.
Although everolimus is an attractive option for conversion therapy in pancreas tx pts that experience SE's of commonly used immunosuppression, TAC and MPA, there is…
2016 American Transplant Congress
Relationship Between Clinical Events and Everolimus Exposure at 12 Months in De Novo Renal Transplant Recipients.
F. Shihab,¹ Y. Qazi,² S. Mulgaonkar,³ K. McCague,⁴ D. Patel,⁴ V. Peddi,⁵ D. Shaffer.⁶
¹University of Utah, Salt Lake City, UT; ²University of Southern California, Los Angeles, CA; ³Barnabas Health, West Orange, NJ; ⁴Novartis Pharmaceuticals Corporation, East Hannover, NJ; ⁵California Pacific Medical Center, San Francisco, CA; ⁶Vanderbilt University, Nashville, TN.
We assessed the incidence of post-transplant biopsy-proven acute rejection (BPAR), graft loss and other adverse events (AEs) associated with everolimus (EVR) and tacrolimus (TAC) exposure…
2016 American Transplant Congress
In Their Own Words: Living Kidney Donors Who Develop Kidney Failure.
L. Ross,¹ C. Halverson,² J. Wang,¹ M. Poulson,³ J. Karlin,⁴ M. Crowley-Matoka.⁵
¹U Chicago, Chicago, IL; ²Anthropology, U Chicago, Chicago, IL; ³Georgetown U, Washington, DC; ⁴Family Medicine, UCSF, San Francisco, CA; ⁵Medical Humanities, Northwestern U, Chicago, IL.
Background: Psychosocial data about living kidney donation have been collected for almost five decades. The results are almost uniformly positive, even in the early years…
2016 American Transplant Congress
Everolimus versus Mycophenolate Mofetil in Combination with Tacrolimus: A Propensity Score Matching Analysis in Liver Transplantation.
P. de Simone,¹ P. Carrai,¹ A. Precisi,² L. Coletti,¹ D. Ghinolfi,¹ F. Filipponi.¹
¹Hepatobiliary Surgery and Liver Transplantation, University of Pisa Medical School Hospitals, Pisa, Italy; ²Laboratory, University of Pisa Medical School Hospital, Pisa, Italy.
Background: No trial has so far investigated everolimus (EVR)-incorporating immunosuppressive regimens versus combined use of tacrolimus (TAC) and mycophenolate mofetil (MMF) in liver transplantation (LT).Materials…
2016 American Transplant Congress
Pre-Transplant Intra-Arterial Liver Directed Therapy Does Not Increase the Risk of Hepatic Arterial Misadventures in Liver Transplantation.
J. Kallini,² A. Gabr,² R. Salem,² R. Lewandowski,² T. Baker.¹
¹Comprehensive Transplant Center, Northwestern University, Chicago, IL; ²Division of Interventional Oncology, Northwestern University, Chicago, IL.
Background: Pretransplant liver directed therapy has emerged as standard of care for patients with end stage liver disease complicated by unresectable hepatocellular cancer. The aim…
2016 American Transplant Congress
Earlier Repletion of Lymphocytes After Alemtuzumab Induction Is Associated with a Lower Incidence of Infection Following Renal Transplantation.
M. Willicombe, D. Goodall, A. McLean, D. Taube.
Imperial College Renal and Transplant Centre, Hammersmith Hospital, London, United Kingdom.
Introduction: Alemtuzumab has been increasingly used as an induction agent in renal transplantation, although the optimal dose is unknown. We have previously reported that alemtuzumab…